Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transcenta Reports Positive Results from Phase I Trial of PD-L1

publication date: May 28, 2021

Transcenta, a Suzhou biotherapeutics company, reported positive results from a Phase I trial of its pH-dependent PD-L1 antibody in pre-treated solid tumor and lymphoma patients. Of the 17 solid tumor patients who could be evaluated for efficacy via biomarkers, 35% had a confirmed partial response at the low dose and 44% at the high dose. The trial did not find any dose limiting toxicities. Transcenta presented the data as an abstract online publication at the 2021 Annual Meeting of the American Society of Clinical Oncology. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital